VR-FLEETCARE
The cooperation of the Finnish rail fleet maintenance company VR FleetCare with the Swedish railway operator SJ AB is evolving. The two companies have signed an agreement to modernise X40 train fleet, with the aim of extending fleet’s life cycle and improving the travel comfort of customers. The agreement now signed, includes a comprehensive modernisation of the X40 fleet's 27 electric trains and an update of the passenger information system. The agreement is worth over EUR 35 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230405005420/en/
VR FleetCare and the Swedish railway operator SJ AB have signed an agreement to modernise X40 train fleet, with the aim of extending fleet’s life cycle and improving the travel comfort of customers. Photo: SJ by Stefan Nilsson. (Photo: Business Wire)
“Above all, I am proud of SJ's confidence in us. The agreement on rolling stock modernisation with SJ is a great opening for us in the Swedish rail fleet maintenance market. The project we won also demonstrates our capabilities and the success of our international growth strategy,” says Otso Ikonen, CEO of VR FleetCare.
The planning and implementation of project will begin immediately and the last of the overhauled X40 series cars will be delivered to the customer in 2027. The work will be carried out in Finland at VR FleetCare's Oulu depot’s project centre and at the Pieksämäki workshop.
Modernisation aim to improve the travel experience
The X40, manufactured by Alstom, is SJ's three-car, two-floor electric multiple unit. The trains were commissioned in 2004–2008. The aim is to carry out a comprehensive renovation of the interior and exterior of the rolling stock, including a modification to the layout of the passenger compartment, the replacement of the seats and lighting, and the modernisation of the passenger information system. The trains’ surfaces will also be treated and painted according to the customer's brand.
Investments at the Oulu depot
VR FleetCare's maintenance units already have a good framework for rolling stock projects, but new solutions are needed for the surface treatment of rolling stock and the transfer of foreign rolling stock on the Finnish railway network. Investments will be made in a modern preparation facility for the Oulu depot’s maintenance hall at the earliest opportunity. In addition, the new transfer adapter bogies to be acquired, which will be suitable for the Finnish track gauge, will ease up the transfer of rolling stock to maintenance units.
More information: VR Mediadesk
We at FleetCare offer our customers maintenance and modernisation services for railway fleet and infrastructure in the Nordic and Baltic countries. We are a rail traffic expert with over 160 years of experience in challenging conditions. Safe freight and passenger traffic is the starting point for all operations. The key to success is our people that consists of over 1000 top tier experts. At VR FleetCare, we add value to our customers by combining our expertise in railways with digital systems, strong partnership network and a continuous strive to review and improve our services together with our customers. VR FleetCare is a subsidiary of the Finnish railway operator VR Group.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom